Strategic Portfolio Recordati Rare Diseases North America is expanding its rare disease portfolio through acquisitions such as Enjaymo from Sanofi and the integration of EUSA Pharma assets, presenting cross-sell and geographic expansion opportunities for complementary orphan therapies.

Rare Disease Focus The company specializes in underserved orphan therapies and engages with rare disease communities to raise awareness and improve diagnosis, indicating opportunities to partner on patient access programs, advocacy collaborations, and early diagnosis campaigns.

Growth Footprint As part of the larger Recordati Group with global operations and a multi-decade history, RRD leverages a broad network to scale launches and distribution, suggesting collaboration potential with international teams for faster market entry and shared clinical development efforts.

Recent Therapeutics Recent acquisitions and launches, including Enjaymo and cysteamine ophthalmic solutions, signal ongoing pipeline expansion and potential for co-promotion, lifecycle management discussions, and enhanced patient access initiatives in North America.

Technology & Outreach Utilizes cloud, web, and digital infrastructure (AWS, Drupal multisite, Cloudflare) alongside awareness campaigns such as #thisCushing, presenting opportunities to tailor digital marketing partnerships, patient engagement platforms, and digital education programs for rare diseases.